Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069525 | 0.91 | KMT2A (0.42) | KMT2AGABRA5ALDH1A1TSHRGHSR | |
| SCHEMBL6069341 | 0.88 | KMT2A (0.47) | KMT2AGABRA5ALDH1A1TSHRGHSR | |
| SCHEMBL6069551 | 0.87 | KMT2A (0.50) | KMT2AGABRA5ALDH1A1TSHRMAPT | |
| SCHEMBL6069614 | 0.85 | KMT2A (0.51) | KMT2AGABRA5ALDH1A1TSHRGHSR | |
| SCHEMBL6642563 | 0.85 | KMT2A (0.54) | KMT2AALDH1A1GHSRMAPTSCN9A | |
| SCHEMBL6069707 | 0.84 | GABRA5 (0.41) | KMT2AGABRA5ALDH1A1MEN1NPSR1 | |
| SCHEMBL6069102 | 0.81 | KMT2A (0.43) | KMT2AGABRA5ALDH1A1TSHRMAPT | |
| SCHEMBL6638254 | 0.81 | KMT2A (0.55) | KMT2AALDH1A1GHSRMAPTSCN9A | |
| SCHEMBL6638257 | 0.81 | KMT2A (0.55) | KMT2AALDH1A1GHSRMAPTSCN9A | |
| SCHEMBL6640226 | 0.80 | KMT2A (0.45) | KMT2AGABRA5GHSRSCN9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037921-B2 | Useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by multidrug resistance protein MRP1 | ELI LILLY AND COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1392702-B1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040097507-A1 | Compounds and methods for inhibiting mrp1 | BONJOUKLIAN ROSANNE (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1392702-A1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002081482-A1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097507-A1 | Compounds and methods for inhibiting mrp1 | ABCC1, ABCB1, ABCB11 | KMT2A 3995/4885GABRA5 4208/4885ALDH1A1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.